Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has reported second-quarter 2026 net product revenue of approximately $13.5 million, a substantial increase from $2 million in the year-ago period. This growth was primarily fueled by approximately $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. The drug recorded 12,592 total prescriptions during the quarter, representing a 100% sequential increase, with new patient prescriptions up 36% and refills soaring 207%. TONMYA currently has coverage for approximately 136 million lives across commercial, managed Medicare, and Medicaid channels, and coverage is expected to expand to approximately 145 million lives when a managed Medicare agreement takes effect on Jan. 1, 2027.
These financial results underscore the commercial viability of TONMYA, which is the first new treatment for fibromyalgia in over 15 years. The strong prescription growth and expanding coverage indicate rapid adoption by patients and prescribers, positioning Tonix for sustained revenue growth. The company's ability to generate significant product revenue is critical as it continues to invest in its robust clinical pipeline.
Tonix has made notable progress in advancing its pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study evaluating TNX-102 SL for major depressive disorder (MDD). Additionally, the company is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These programs highlight Tonix's commitment to addressing high unmet medical needs in central nervous system (CNS) and immunology.
The company ended the quarter with approximately $176.2 million in cash and cash equivalents. Management stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides the company with the flexibility to execute its strategic plans and potentially bring new therapies to market.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on CNS and immunology treatments. Its commercial portfolio includes TONMYA and acute migraine products Zembrace SymTouch and Tosymra. The company is also developing TNX-2900 for Prader-Willi syndrome, a rare disease, and advancing immunology programs such as TNX-1500 for kidney transplant rejection prevention.
The impressive Q2 results and pipeline progress underscore Tonix's transformation into a commercial-stage biotech with multiple growth catalysts. As TONMYA continues to gain market share and the pipeline advances, the company is well-positioned to create long-term shareholder value. Investors and industry observers will be watching closely for further updates on coverage expansion and clinical trial milestones.
